LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced expanded European indications for its NanoKnife System to include soft tissue ablation for tumors of the liver, pancreas, kidney, and prostate, including in patients with intermediate-risk prostate cancer. The expan
Tag: AngioDynamics
AngioDynamics and The PERT Consortium® Launch Investigator-Led Research Fund to Advance Pulmonary Embolism Care
The ALPHA-PE Research Fund Supports Independent, Physician-Led Studies to Advance Real-World PE Evidence LATHAM, N.Y.–Feb. 5, 2026– AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, and […]
AngioDynamics to Convene Cardiovascular Leaders at Scientific Forum as Pipeline Continues to Advance
Physician-led Collaboration Reinforces Ongoing Regulatory Activity and Clinical Advancement Across the Cardiovascular Portfolio LATHAM, N.Y.–Feb. 3, 2026– AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced it will […]
AngioDynamics to Report Fiscal 2026 Second Quarter Results on January 6, 2026
LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the second quarter of fiscal year 2026 […]
AngioDynamics Reports Fiscal Year 2026 First Quarter Financial Results; Med Tech Growth of 26.1% Drives Continued Momentum
Med Tech segment delivers fourth consecutive quarter of over 20% revenue growth Reported Adjusted EBITDA of $2.2 million compared to ($0.2) million in the prior year Continues to expect to be cash flow positive for the full fiscal year 2026 Raised full year FY 2026 guidance for net sales, Med […]
AngioDynamics Enrolls First Patient in AMBITION BTK Trial Advancing Treatment for Critical Limb Ischemia
Trial Investigates Use of Auryon Atherectomy System in Cases with Challenging Below-the-Knee Blockages LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced enrollment of the first […]
AngioDynamics Announces Publication of PRESERVE Study of NanoKnife® System for Prostate Tissue Ablation in European Urology
Peer-reviewed findings demonstrate high disease control and quality-of-life preservation, supporting shift toward focal therapy in prostate treatment LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of […]
AngioDynamics to Report Fiscal 2025 Fourth Quarter and Full-Year Financial Results on Tuesday, July 15, 2025
LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the fourth quarter and fiscal year 2025 […]
AngioDynamics Reports Fiscal Year 2025 Third Quarter Financial Results
LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the third quarter of fiscal year 2025, which ended February […]
AngioDynamics to Present at the Oppenheimer 35th Annual Healthcare MedTech and Services Virtual Conference
March 10, 2025 04:30 PM Eastern Daylight Time LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that Jim Clemmer, President and […]



